Key result
SMAD2 inhibition with SM16 preserved cardiac function in mice subjected to aortic banding, increasing fractional shortening by 38% compared to controls.
Why the study?
Does SM16 preserve cardiac function and attenuate remodeling in mice subjected to pressure overload via aortic banding?
Does SM16 preserve cardiac function and attenuate remodeling in mice subjected to pressure overload via aortic banding?
Pharmacological inhibition of SMAD2 signaling with SM16 attenuates cardiomyocyte hypertrophy and preserves cardiac function in a mouse model of pressure overload.
Answers are grounded in this paper and cite their sources.
SM16 should not yet inform clinical practice; leaves open whether SMAD2 inhibition attenuates human pressure-overload remodeling.
AIMS: Left ventricular (LV) pressure overload leads to myocardial remodelling and reduced cardiac function. Both cardioprotective and deleterious effects have been attributed to SMAD2/3 (SMAD, small mothers against decapentaplegic) signalling, but the role of these important molecules in pressure overload remains unclear. The aim of this study was to examine the effects of SMAD2 inhibition on cardiac function and remodelling in mice subjected to aortic banding (AB), using a small molecule inhibitor (SM16) of SMAD2 signalling. METHODS AND RESULTS: C57BL/6 mice were subjected to 1 week of AB, which led to a three-fold increased phosphorylation of SMAD2 that was reduced by SM16 (P≤ 0.05), as measured by western blotting. Cardiac function was evaluated by echocardiography and was preserved by SM16, as fractional shortening was increased by 38% (P≤ 0.05) and mitral flow deceleration reduced by 28% compared with AB mice not receiving SM16 (P≤ 0.05). In accordance with this, SM16 abolished the 21% increase in lung weight in AB mice (P≤ 0.05). Cardiomyocyte hypertrophy and foetal gene expression, as measured by qPCR, were also reduced. Myocardial collagen protein was unaltered 1 week after AB. LV sarcoplasmic reticulum Ca(2+)ATPase (SERCA2) reduction in AB mice and in transforming growth factor-β1-stimulated rat cardiomyocytes was diminished by SM16. Ca(2+) transient decay kinetics were improved in cardiomyocytes isolated from AB mice receiving SM16. CONCLUSION: In pressure overload, pharmacological inhibition of SMAD2 signalling attenuated cardiomyocyte hypertrophy and preserved cardiac function. SM16 prevented SMAD2-mediated downregulation of SERCA2 in vivo and in cardiomyocytes, suggesting improved cardiomyocyte Ca(2+) handling as a possible cardioprotective mechanism.
No takes yet. Share an insight, caveat, or question.
Bjørnstad et al. (2011) studied Left ventricular pressure overload. SM16 (SMAD2 inhibitor) vs. Aortic banding without SM16 was evaluated on Cardiac function (fractional shortening) (p=≤0.05). SMAD2 inhibition with SM16 preserved cardiac function in mice subjected to aortic banding, increasing fractional shortening by 38% compared to controls.
Synapse has enriched 10 related papers. Consider them for comparative context: